Hetero Launches Once-Weekly Semaglutide Truglyx in Kenya as Novo Nordisk Brings Ozempic and Wegovy to Market
核心洞察
Hetero launched its once-weekly semaglutide injection Truglyx (搜索) in Kenya at a Nairobi symposium attended by more than 300 physicians focused on diabetes and obesity (搜索).
Novo Nordisk separately introduced Ozempic for type 2 diabetes (搜索) and Wegovy for weight management in Kenya, citing a 142 percent rise in African diabetes prevalence over ten years.
Hetero said Truglyx (搜索) demonstrated bioequivalence to the reference semaglutide product, with 24-week clinical data showing improved glycemic control and weight reduction.
Kenya's metabolic disease treatment landscape expanded on two fronts as Hetero launched its once-weekly semaglutide injection Truglyx (搜索) and Novo Nordisk introduced Ozempic and Wegovy, with both companies and attending specialists framing the moves around the country's rising burden of diabetes and obesity (搜索).
More than 300 physicians from across Kenya gathered in Nairobi for a scientific symposium, titled "Reset Diabesity," where Hetero officially launched Truglyx (搜索) into the Kenyan market. The meeting brought together specialists from multiple disciplines to address the increasing prevalence of what experts describe as "diabesity" — the close relationship between obesity (搜索), type 2 diabetes (搜索) and associated cardio-renal-metabolic complications.
Hetero Positions Truglyx on Bioequivalence and Affordability
Truglyx (搜索) is Hetero's once-weekly injectable GLP-1 receptor (搜索) agonist containing semaglutide. According to experts at the symposium, the medicine is intended to help patients manage both blood glucose levels and body weight through a single treatment approach, while also potentially reducing cardiovascular risk and supporting kidney health in people living with diabetes and obesity (搜索).
Hetero said Truglyx (搜索) has demonstrated bioequivalence to the reference semaglutide product and is manufactured using a global-quality platform designed to ensure safety, reliability and consistent clinical performance. The company cited clinical data indicating that patients treated with its semaglutide over 24 weeks experienced improvements in blood sugar control, fasting and post-meal glucose levels, as well as reductions in body weight.
"With the launch of Truglyx (搜索) in Kenya, we are taking another important step towards expanding access to advanced diabetes and metabolic care in emerging markets," said Hetero Director of Marketing Murali Krishna Reddy Bheemireddy. "Our focus has been on delivering a high-quality, affordable semaglutide that meets global scientific and regulatory standards while remaining practical for real-world clinical use."
The symposium was moderated by endocrinologist Dr. Paul Ngugi and featured presentations from consultant interventional cardiologist Dr. Swaleh Breik Misfar and consultant endocrinologist Dr. Kirtida Acharya.
Dr. Acharya said diabetes and obesity (搜索) should no longer be viewed as separate conditions but as part of a broader metabolic dysfunction linked to cardiovascular disease, chronic kidney disease (搜索), certain cancers and mental health disorders. She called for stronger government involvement through public awareness campaigns, improved training for healthcare professionals and increased investment in locally generated clinical research, and urged clinicians to overcome what she described as "clinical inertia" by intervening earlier before patients develop serious complications.
Novo Nordisk Launch Highlights Screening Gaps and Pricing
Novo Nordisk hosted a separate scientific launch event in Nairobi to introduce Ozempic for the management of type 2 diabetes (搜索) and Wegovy for weight management in people living with obesity (搜索) or overweight with associated health conditions. The event convened healthcare professionals, experts, policymakers and other stakeholders to discuss diabetes and obesity care, the science underpinning new treatment options, and the role of partnerships and innovation in responding to unmet needs in Kenya and across Africa.
Consultant physician and endocrinologist Dr. Roseline Ngugi said Kenya is confronting a significant but often under-recognised burden of diabetes, with many people living with the condition without knowing it. She cited a sharp increase in diabetes prevalence across Africa over the past decade and noted that the challenge extends beyond diagnosed cases, with a substantial proportion of people in Kenya believed to be living with diabetes without awareness of their condition — making early screening and diagnosis an important part of changing the trajectory of diabetes care.
"Africa alone has seen a rise in the prevalence of diabetes of over 142 per cent in the last ten years," she said.
Dr. Ngugi also drew attention to the relationship between obesity (搜索) and other chronic conditions, including hypertension (搜索), arguing the condition needs to be understood within the broader context of metabolic health rather than only through the lens of individual lifestyle choices. "Obesity is not a lifestyle disease. It is a metabolic condition closely causing cardio-metabolic diseases," she said. She noted that obesity is increasingly being observed among different population groups, including children, pointing to the need for healthcare systems to move beyond treating individual conditions in isolation.
Access, Affordability and Responsible Prescribing
Speakers at the Novo Nordisk launch emphasised that the impact of innovation will ultimately depend on whether patients who need treatment can access it. Dr. Ngugi said affordability and accessibility have historically presented significant barriers to treatment and welcomed the reduction in the price of the medicines announced in connection with their introduction in Kenya.
"One of the problems we had is accessibility. However, I am excited to announce that the price they are offering is affordable," she said, calling for greater engagement by health insurers, government and other stakeholders in considering how appropriate treatment can contribute to reducing the longer-term cost of managing chronic disease and its complications.
The discussion also underscored the importance of ensuring that access to medicines is accompanied by responsible prescribing and appropriate patient assessment. Healthcare professionals are being equipped with information on patient eligibility, prescribing and the appropriate use of the medicines, reinforcing the principle that treatment decisions should be made within a healthcare professional–patient relationship.
Malika De Maillard, Head of Novo Nordisk Business Area Africa, provided insights into the science behind the treatment options and the changing landscape of diabetes and obesity (搜索) care, noting the extensive global experience with Novo Nordisk's diabetes and obesity medicines and the continuing medical need among people living with chronic metabolic conditions. "There is a great medical need for diabetic patients," she said, highlighting growing recognition of the relationship between obesity, diabetes and other cardio-metabolic conditions, including cardiovascular and kidney disease.
Partnerships and Health-System Implications
The Novo Nordisk launch also provided a platform to explore international partnerships in strengthening healthcare systems. Stephan Schønemann, Danish Ambassador to Kenya, highlighted the longstanding relationship between Denmark and Kenya and the potential for cooperation in healthcare, innovation and knowledge exchange, describing the introduction of additional treatment options as an opportunity to strengthen choices within diabetes care. "We are giving people with diabetes a better option," he said, pointing to differences in health outcomes between Denmark and Kenya, including life expectancy.
The conversation extended beyond the introduction of the medicines to a broader question relevant to African health systems: how to better prevent, identify and manage conditions that increasingly occur together, as changing lifestyles, urbanisation, demographic shifts and persistent gaps in screening and diagnosis reshape the burden of non-communicable diseases.